Dermira (NASDAQ:DERM) has earned an average rating of “Hold” from the nine brokerages that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $28.00.
A number of equities research analysts have recently weighed in on the stock. BidaskClub upgraded shares of Dermira from a “hold” rating to a “buy” rating in a report on Tuesday, January 30th. Cantor Fitzgerald set a $45.00 price objective on shares of Dermira and gave the stock a “buy” rating in a report on Monday, January 15th. Zacks Investment Research lowered shares of Dermira from a “hold” rating to a “sell” rating in a report on Tuesday, February 27th. Leerink Swann boosted their price objective on shares of Dermira from $42.00 to $48.00 and gave the stock an “outperform” rating in a report on Wednesday, January 17th. Finally, Mizuho restated a “buy” rating on shares of Dermira in a report on Friday, February 23rd.
In related news, insider Eugene A. Bauer sold 3,000 shares of the company’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $28.55, for a total transaction of $85,650.00. Following the completion of the sale, the insider now directly owns 5,802 shares in the company, valued at approximately $165,647.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 4,700 shares of company stock valued at $131,142 over the last quarter. 13.30% of the stock is currently owned by company insiders.
A number of large investors have recently bought and sold shares of DERM. Aperio Group LLC bought a new stake in Dermira during the 4th quarter valued at $213,000. SG Americas Securities LLC raised its holdings in Dermira by 47.7% during the 3rd quarter. SG Americas Securities LLC now owns 8,130 shares of the biopharmaceutical company’s stock valued at $220,000 after buying an additional 2,627 shares during the last quarter. Two Sigma Advisers LP bought a new stake in Dermira during the 4th quarter valued at $222,000. Teacher Retirement System of Texas bought a new stake in Dermira during the 4th quarter valued at $283,000. Finally, Landscape Capital Management L.L.C. bought a new stake in Dermira during the 4th quarter valued at $429,000. Institutional investors own 94.93% of the company’s stock.
Shares of DERM opened at $8.92 on Wednesday. The company has a market capitalization of $360.09, a PE ratio of -2.03 and a beta of 1.52. The company has a debt-to-equity ratio of 1.87, a current ratio of 5.28 and a quick ratio of 5.28. Dermira has a fifty-two week low of $6.98 and a fifty-two week high of $34.45.
Dermira (NASDAQ:DERM) last announced its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.25) by ($0.09). The business had revenue of $1.34 million during the quarter, compared to the consensus estimate of $1.10 million. Dermira had a negative return on equity of 62.07% and a negative net margin of 6,678.29%. equities research analysts expect that Dermira will post -4.81 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This story was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/21/dermira-derm-receives-28-00-average-price-target-from-brokerages.html.
Dermira Company Profile
Dermira, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies to treat dermatologic diseases. The company's product candidates include Glycopyrronium tosylate, a novel form of an anticholinergic agent that has completed Phase III clinical trial for the treatment of primary axillary hyperhidrosis; Olumacostat glasaretil, a novel small molecule designed to target sebum production, which is in Phase III clinical trial for the treatment of acne vulgaris; and lebrikizumab, a novel humanized monoclonal antibody targeting interleukin 13 that is in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis.
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.